秋好 健志 (アキヨシ タケシ)

Akiyoshi, Takeshi

写真a

所属(所属キャンパス)

薬学部 薬学科 臨床薬物動態学講座 (芝共立)

職名

専任講師

総合紹介 【 表示 / 非表示

 

著書 【 表示 / 非表示

  • MRテキスト2018, 医薬品情報.

    大谷壽一(編), 大谷壽一, 秋好健志., 南山堂, 東京, 2018年01月

    担当範囲: 16-38

  • MRテキストI, 医薬品情報2012. 2015改訂

    大谷壽一, 岡淳一郎, 折井孝男(編), 大谷壽一, 秋好健志, 他執筆., 南山堂, 東京, 2015年

    担当範囲: 80-109

  • MRテキストI, 医薬品情報2012.

    大谷壽一, 岡淳一郎, 折井孝男(編), 大谷壽一, 秋好健志, 他執筆., 南山堂, 東京, 2012年01月

    担当範囲: 80-129

論文 【 表示 / 非表示

  • Novel method to estimate the appropriate dosing interval for activated charcoal to avoid interaction with other drugs.

    Ohtani H, Nakamura K, Imaoka A, Akiyoshi T

    European journal of clinical pharmacology (European Journal of Clinical Pharmacology)  76 ( 11 ) 1529 - 1536 2020年09月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  0031-6970

     概要を見る

    © 2020, Springer-Verlag GmbH Germany, part of Springer Nature. Purpose: Activated charcoal is known to adsorb a variety of drugs concomitantly administered and reduce their intestinal absorption, and separating the dosing is considered a practical approach to avoid this drug interaction. The aim of the present study was to develop and validate a simple method to estimate the sufficient dosing interval to avoid drug interaction using the pharmacokinetic profile of the subject drugs administered alone and the amplitude of interaction upon simultaneous administration with activated charcoal. Methods: For each subject drug, the pharmacokinetic profile and the amplitude of interaction, as assessed by AUCR (the ratio of area under the plasma concentration-time curve (AUC) in the presence of activated charcoal to that in its absence), were collected from previous reports. The AUCR value was estimated based on the compartment model under the assumption that the subject drug in the first gastrointestinal compartment is immediately adsorbed to a certain extent upon the administration of activated charcoal. The estimated AUCR (AUCRe) for each drug with certain dosing interval was compared with the respective AUCR value reported previously (AUCRobs). Results: Among twenty concentration profiles for 14 subject drugs obtained from previous reports, 15 AUCRe values fell in the range of 80–120% of the respective AUCRobs values. Conclusion: The developed method enabled estimation of the amplitude of DDI by activated charcoal administered in a certain dosing interval, whereas overestimation of AUCRe was observed for drugs that undergo extensive enterohepatic circulation.

  • Profile of the inhibitory effects of gefitinib on CYP2D6 variants in vitro
.

    Semba Y, Akiyoshi T, Hibino H, Imaoka A, Ohtani H

    International journal of clinical pharmacology and therapeutics (International journal of clinical pharmacology and therapeutics)  58 ( 10 ) 539 - 542 2020年07月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  0946-1965

     概要を見る

    OBJECTIVE: CYP2D6 is a highly polymorphic metabolic enzyme with more than 100 genetic variants, some of which are associated with significantly altered enzyme activity, such as CYP2D6.2 (Arg296Cys, Ser486Thr), CYP2D6.10 (Pro34Ser, Ser486Thr), and CYP2D6.39 (Ser486Thr). Gefitinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) and is used to treat non-small-cell lung cancer with EGFR mutations. Gefitinib is known to competitively inhibit CYP2D6 activity. The aim of this study was to quantitatively compare the inhibitory effects of gefitinib on CYP2D6 enzyme kinetics among CYP2D6 variants. MATERIALS AND METHODS: The enzymatic activity of several CYP2D6 genetic variants; i.e., CYP2D6.1 (wild type), CYP2D6.2, CYP2D6.10, and CYP2D6.39, was assessed by examining the O-demethylation of dextromethorphan. RESULTS AND CONCLUSION: The intrinsic clearance of dextromethorphan (Vmax/Km) for CYP2D6.2, CYP2D6.10, and CYP2D6.39 were 0.565-, 0.0376-, and 0.470-fold of that for wild type, respectively. For all variants, the mixed inhibition model was better at explaining the nature of the inhibitory effects of gefitinib than the competitive inhibition model. However, the inhibitory potency of gefitinib varied among the CYP2D6 genetic variants. The Ki values for CYP2D6.2, CYP2D6.10, and CYP2D6.39 were 1.4-, 2.5- and 1.5-fold higher than that for wild type, respectively, implying that these variants are less susceptible to the inhibition by gefitinib. The genetic variations in CYP2D6 might be one of the factors responsible for inter-individual differences in the strength of CYP2D6-mediated drug interactions involving gefitinib.

  • pH-dependent transport kinetics of the human organic anion-transporting polypeptide 1A2.

    Morita T, Akiyoshi T, Sato R, Katayama K, Yajima K, Kataoka H, Imaoka A, Sugimoto Y, Ohtani H

    Drug metabolism and pharmacokinetics (Drug Metabolism and Pharmacokinetics)  35 ( 2 ) 220 - 227 2020年04月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  1347-4367

     概要を見る

    © 2019 The Japanese Society for the Study of Xenobiotics Organic anion-transporting polypeptide (OATP) 1A2 is expressed on the apical sides of intestinal and renal epithelial cells and considered to be involved in the intestinal absorption and renal reabsorption of drugs. Although the transport activity of OATP1A2 is considered to be pH-dependent, the effects of pH on its kinetic parameters and on the potency of OATP1A2 inhibitors are yet to be elucidated. Some OATP are known to have multiple binding sites (MBS), but it remains unclear whether OATP1A2 has MBS. In the present study, we evaluated the influence of pH on the OATP1A2-mediated uptake of estrone 3-sulfate using OATP1A2-expressing HEK293 cells. The uptake of 0.3 μM estrone 3-sulfate by HEK293-OATP1A2 cells was pH-dependent. OATP1A2 exhibited bimodal saturation kinetics at pH 6.3 and 7.4. Compared with that seen at pH 6.3 (5.62 μM), the Km value of the high-affinity site was 8-fold higher at pH 7.4 (43.2 μM). In addition, the influence of pH on the potency of inhibitors varied among the examined inhibitors. These results suggest that the transport properties of OATP1A2 under lower pH conditions, such as those found in the microenvironments of the small intestinal mucosa and distal tubules, differ from those seen under neutral pH conditions.

  • 医薬品の第三者への転売・譲渡の違法性に関する消費者の意識調査.

    大谷壽一, 藤井萌未, 今岡鮎子, 望月真弓, 山浦克典, 秋好健志.

    医薬品情報学 22 ( 1 ) 30 - 34 2020年

    研究論文(学術雑誌), 共著, 査読有り

  • Irinotecan-induced gastrointestinal damage impairs the absorption of dabigatran etexilate.

    Hattori T, Imaoka A, Akiyoshi T, Ohtani H

    Biopharmaceutics & drug disposition (Biopharmaceutics and Drug Disposition)  40 ( 9 ) 315 - 324 2019年11月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  0142-2782

     概要を見る

    © 2019 John Wiley & Sons, Ltd. Irinotecan causes serious gastrointestinal damage. Dabigatran etexilate (DABE), an oral anticoagulant and substrate of P-glycoprotein (P-gp), is poorly absorbed and exhibits low bioavailability in humans. The aim of this study was to evaluate the effects of irinotecan-induced gastrointestinal damage on the pharmacokinetics/pharmacodynamics (PK/PD) of DABE. Irinotecan was administered intravenously to rats for 4 days to induce gastrointestinal damage. To investigate the PK profile of dabigatran (DAB), an active moiety of DABE, DABE was administered orally on day 5, and then DAB was administered intravenously on day 6. To evaluate the PD profile of DAB, the activated partial thromboplastin time (APTT) was measured. The protein expression level of intestinal P-gp was evaluated. In the irinotecan-treated rats, the area under the concentration–time curve of DAB after the oral administration of DABE and the bioavailability of DABE were decreased significantly. The APTT ratio also decreased, suggesting that the impaired efficacy of DABE was attributable to a reduction in its bioavailability. The expression of intestinal P-gp was higher in the irinotecan-treated rats. Taking into consideration the histological damage caused to the intestinal epithelium, both the increased P-gp expression and the reduced passive diffusion were considered to be responsible for the reduction in the bioavailability of DABE.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

総説・解説等 【 表示 / 非表示

  • Epstein-Barr-Virus 感染癌細胞における microRNA を介した癌転移機構の解明

    秋好 健志

    Annual Report of YOKOYAMA Foundation for Clinical Pharmacy 25   58 - 60 2017年

    総説・解説(商業誌、新聞、ウェブメディア), 単著

  • P450を介した薬物相互作用に個人差をもたらす遺伝的要因の定量的解明と予測

    秋好 健志 大谷壽一 今岡鮎子

    臨床薬理の進歩 (臨床薬理研究振興財団)     128 - 129 2016年

    総説・解説(商業誌、新聞、ウェブメディア)

研究発表 【 表示 / 非表示

  • CYP2C9 遺伝的変異型における resveratrol および sesamin の阻害特性の比較

    稲田理乃, 秋好健志, 今岡鮎子, 大谷壽一.

    日本薬学会第 140 年会 (京都) , 2020年03月, ポスター(一般), 日本薬学会

  • CYP2C19 変異型分子種の代謝活性に及ぼす温度の影響.

    趙澄江, 秋好健志, 渡辺大智, 関 博行, 今岡鮎子, 山崎浩史, 下地みゆき, 中村克徳, 大谷壽一.

    日本薬学会第 140 年会 (京都) , 2020年03月, ポスター(一般), 日本薬学会

  • High and low affinity kinetics of OATP2B1 - Inhibitory potency and pH-dependency of inhibitors

    佐藤 稜, 秋好健志, 今岡鮎子, 植草義徳, 木内文之, 片山和浩, 杉本芳一, 大谷壽一.

    日本薬物動態学会 第 34 年会, 2019年12月, 口頭(一般)

  • Identification and characterization of a novel OATP2B1 inhibitor from citrus fruits juice

    森田時生, 秋好健志, 矢島広大, 今岡鮎子, 片山和浩, 杉本芳一, 大谷壽一.

    第 13 回 次世代を担う若手医療薬科学シンポジウム. (岐阜) , 2019年10月, ポスター(一般), 日本薬学会医療薬科学部会

  • Comparative analysis of CYP2C19 enzyme kinetics among six genetic variants.

    Watanabe D, Shimoji M, Seki H, Akiyoshi T, Imaoka A, Murakami A, Kishimoto H, Murayama N, Yamazaki H, Nakamura K, Ohtani H.

    Asian Association of Schools of Pharmacy Conference. (Suwon, Korea) , 2019年07月, ポスター(一般), Asian Association of Schools of Pharmacy

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • フェキソフェナジンと各種柑橘類の消化管吸収過程における相互作用リスクの評価

    2020年06月
    -
    2021年03月

    公益財団法人 一般用医薬品セルフメディケーション振興財団, 令和2年度調査・研究助成金, 秋好健志, 補助金,  代表

  • 標的絶対定量プロテオーム解析を用いた抗がん剤曝露下での薬物輸送担体発現変動解明

    2020年04月
    -
    2021年03月

    中冨健康科学振興財団, 第32回中冨健康科学振興財団 「研究助成金」, 秋好健志, 補助金,  代表

  • 抗がん剤による薬物トランスポーターの発現変動~メカニズムと薬物体内動態への影響~

    2019年04月
    -
    2022年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 秋好 健志, 基盤研究(C), 補助金,  代表

  • Epstein-Barr-Virus感染癌細胞におけるmicroRNAを介した転移機構の解明

    2017年04月
    -
    2019年03月

    薬学研究奨励財団, 薬学研究奨励財団 研究助成金, 秋好健志, 補助金,  代表

  • Epstein-Barr-Virus感染癌細胞におけるmicroRNAを介した転移機構の解明

    2016年11月
    -
    2017年10月

    一般財団法人横山臨床薬理研究助成基金, 研究助成金, 秋好健志, 補助金,  代表

全件表示 >>

受賞 【 表示 / 非表示

  • 優秀ポスター発表賞

    森田時生,佐藤稜,秋好健志, 今岡鮎子, 片山和浩, 杉本芳一, 大谷壽一. , 2018年09月, 第62回日本薬学会関東支部会, ヒト小腸有機アニオン輸送ポリペプチド OATP1A2 および OATP2B1 の pH sensitive な輸送特性の解析.

    受賞区分: 国内学会・会議・シンポジウム等の賞,  受賞国: 日本

  • 優秀口演発表賞

    土谷聡耀, 今岡鮎子, 秋好健志, 大谷壽一, 2017年09月, 第61回日本薬学会関東支部大会, イリノテカンによる消化管障害がジゴキシンの吸収に与える影響

    受賞国: 東京

  • 学生優秀発表賞

    ○中村 幸大, 今岡 鮎子, 秋好 健志, 大谷 壽一, 慶應大・薬., 2017年07月, 第20回日本医薬品情報学会総会・学術大会, 医薬品と活性炭との相互作用の回避のための投与設計法の構築と評価

  • 優秀発表賞

    ○今岡 鮎子, 関 耕平, 秋好 健志, 大谷 壽一., 2017年06月, 日本医療薬学会「第1回フレッシャーズ・カンファランス」, 薬物吸収に対する胃内 pH および食事の影響 -小動物を用いた評価-

  • 優秀発表賞

    ○四元 敬一, 今岡 鮎子, 秋好 健志, 大谷 壽一., 2017年06月, 日本医療薬学会「第1回フレッシャーズ・カンファランス」, 5-FU誘発性消化管障害時のジゴキシンの吸収変動

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • Thai Pharmacy Experience

    2020年度

  • 課題研究(臨床薬物動態学)

    2020年度

  • 演習(臨床薬物動態学)

    2020年度

  • 卒業研究1(薬学科)

    2020年度

  • 実務実習事前学習2

    2020年度

全件表示 >>